Vascular endothelial growth factor inhibitors outcomes in good vision eyes with neovascular age-related macular degeneration: Fight Retinal Blindness! SPAIN Report 4.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sánchez-Vela Laura, Brosa Helena, Martin-Pinardel Ruben, Bernal-Morales Carolina, Parrado-Carrillo Alba, Moll-Udina Aina, Puzo-Bayod Martín, Garay-Aramburu Gonzaga, Arruabarrena Carolina, Sararols-Ramsay Laura, Calvo-Perez Pilar, Zapata Miguel Angel, Garrido Marta, Abraldes Maximino, Ruiz-Moreno José María, Broc-Iturralde Laura, Velázquez-Villoria Daniel, Escobar-Barranco José Juan, Gallego-Pinazo Roberto, Figueroa Marta S, García-Layana Alfredo, Figueras-Roca Marc, Gillies Mark C, Casaroli-Marano Ricardo P, Zarranz-Ventura Javier, from the writing committee of the Fight Retinal Blindness Spain (FRB! Spain) Users Group
Аннотация
METHODS: Multicentre, real-world, and national database study. Demographics, VA, number of injections, and patient visit data were collected using a validated online tool. Subgroup analysis included 2 nonoverlapping participant groups defined by baseline VA: Good vision eyes (GVE, "70-100 letters") and non-GVE ("0-69 letters") at 12, 24, and 36 months.
RESULTS: A total of 3 138 eyes (2 520 patients) were included in the analysis, followed up for 12 (n = 2 426; 77.3%), 24 (n = 1 793; 57.1%), and 36 months (n = 1 167; 37.2%). GVE had significantly better 24-month final VA (71.0 ± 13.8 vs 52.3 ± 23.2; p < 0.001) than NGVE. Mean VA change (letters) at 12, 24, and 36 months of follow-up was significantly lower in the GVE -2.4 (-3.1, -1.6), -4.5 (-5.6, -3.5), and -7.8 (-9.4, -6.2) than in NGVE +6.7 (5.8, 7.6), +5.0 (3.8, 6.2), and +4.0 (2.5, 5.5) group, respectively. The number of injections and percentage of visits with active lesions were higher in GVE through 36 months.
CONCLUSIONS: The mean VA of GVE tends to drop, but it is still much higher than NGVE eyes at 12, 24, and 36 months. Early detection and prompt treatment are key and should be considered in treatment access policies, regulatory frameworks, and clinical guidelines, as defining a threshold to start treatment may have a clear impact on final visual function, patient autonomy and legal blindness rates in nAMD patients.